EP0003089B1 - Drier for silkscreen printed sheets - Google Patents
Drier for silkscreen printed sheets Download PDFInfo
- Publication number
- EP0003089B1 EP0003089B1 EP19780400265 EP78400265A EP0003089B1 EP 0003089 B1 EP0003089 B1 EP 0003089B1 EP 19780400265 EP19780400265 EP 19780400265 EP 78400265 A EP78400265 A EP 78400265A EP 0003089 B1 EP0003089 B1 EP 0003089B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- hurdle
- conveyor
- sheet
- clips
- bent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
- B41F—PRINTING MACHINES OR PRESSES
- B41F23/00—Devices for treating the surfaces of sheets, webs, or other articles in connection with printing
- B41F23/04—Devices for treating the surfaces of sheets, webs, or other articles in connection with printing by heat drying, by cooling, by applying powders
- B41F23/044—Drying sheets, e.g. between two printing stations
- B41F23/0443—Drying sheets, e.g. between two printing stations after printing
- B41F23/0446—Wicket conveyors
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F26—DRYING
- F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
- F26B15/00—Machines or apparatus for drying objects with progressive movement; Machines or apparatus with progressive movement for drying batches of material in compact form
- F26B15/02—Machines or apparatus for drying objects with progressive movement; Machines or apparatus with progressive movement for drying batches of material in compact form with movement in the whole or part of a circle
- F26B15/08—Machines or apparatus for drying objects with progressive movement; Machines or apparatus with progressive movement for drying batches of material in compact form with movement in the whole or part of a circle in a vertical plane
- F26B15/085—Machines or apparatus for drying objects with progressive movement; Machines or apparatus with progressive movement for drying batches of material in compact form with movement in the whole or part of a circle in a vertical plane with endless clamp or tray conveyor, e.g. wicket conveyor
Definitions
- the present invention relates to a dryer for sheets printed by screen printing.
- the drying of the sheets printed by screen printing is done at present, either manually by stacking on each other drying racks on each of which is placed a sheet, or mechanically by means of dryers in which blows air on the moving leaves.
- a first known type of embodiment is thus constituted by a rectilinear tunnel inside which a rotating conveyor is arranged, an infrared or other heating device being additionally placed in the tunnel in association with an air ventilation system. Leaving the tunnel, the leaves are dry and are removed from the machine.
- a second known type of embodiment consists of an endless conveyor rotating around axes placed at its ends, and which carries racks on which the printed sheets are placed.
- This type of dryer is as long as the forced air tunnels, because only a very weak or no air flow allows only the laid leaves to stay in place.
- Another disadvantage of this type of dryer is that the insufficiently rigid sheets touch the previous rack, which limits the possibility of use.
- GB-A-793 216 describes a dryer without racks, in which the sheets are dried by blowing hot air flat on a table located in the upper part of the dryer.
- the absence of racks is very annoying since the leaves can come to press against each other during their movement.
- the insertion of the sheets into the tongs and their unloading are done in two separate consecutive operations.
- This conveyor 1 is carried by a frame 5 in the middle of which is arranged a device 6 for blowing air of a type known per se.
- Each series of pliers 9 is constituted, in the example shown, by a row of bent blades 12 (FIG. 3), rotatably mounted around axes or pins 13 parallel to the adjoining side of the rack 7, secured to the endless conveyor 1
- the blades 12, preferably metallic, are bent in the example shown by forming an angle of approximately 120 degrees, the axes 13 being placed inside this angle, and supporting the blades 12 by means of ears 14 integral with the blades and in which the pins 13 are threaded.
- the mooring device constituted by the clamps according to the invention, it is possible to ventilate with increased force, the sheets dry more quickly.
- a lower number of racks is necessary to dry a determined quantity of sheets in a given time interval, which makes it possible to reduce the size of the machine by reducing the number of racks which it can contain.
- the automatic opening and closing device can be produced in any other way equivalent to that described and shown in FIG. 3, for example by having fixed cams roughly similar to the heads 17 and on which the clamps would come. '' open when reaching horizontal.
Description
La présente invention a pour objet un séchoir pour feuilles imprimées par sérigraphie.The present invention relates to a dryer for sheets printed by screen printing.
Comme on le sait, le séchage des feuilles imprimées par sérigraphie se fait à l'heure actuelle, soit manuellement en empilant les unes sur les autres des claies de séchage sur chacune desquelles est disposée une feuille, soit mécaniquement au moyen de séchoirs dans lesquels on souffle de l'air sur les feuilles en mouvement.As is known, the drying of the sheets printed by screen printing is done at present, either manually by stacking on each other drying racks on each of which is placed a sheet, or mechanically by means of dryers in which blows air on the moving leaves.
Un premier type de réalisation connu est ainsi constitué par un tunnel rectiligne à l'intérieur duquel est disposé un tapis tournant, un dispositif de chauffage à infrarouge ou autre étant complémentairement placé dans le tunnel en association avec un système de ventilation de l'air. A lar sortie du tunnel, les feuilles sont sèches et sont retirées de la machine.A first known type of embodiment is thus constituted by a rectilinear tunnel inside which a rotating conveyor is arranged, an infrared or other heating device being additionally placed in the tunnel in association with an air ventilation system. Leaving the tunnel, the leaves are dry and are removed from the machine.
Ces tunnels sont extrêmement encombrants, consomment en outre une grande quantité d'énergie de chauffage, ce qui rend leur exploitation onéreuse, ils empêchent un repérage précis parce que la chaleur dessèche et par conséquent déforme les feuilles. Enfin, ils obligent à ne se servir que de sérise d'encres étudiées pour eux, limitant ainsi le choix de l'utilisateur.These tunnels are extremely bulky, also consume a large amount of heating energy, which makes them expensive to operate, they prevent precise location because the heat dries up and therefore deforms the leaves. Finally, they oblige to use only a serise of inks studied for them, thus limiting the choice of the user.
Un second type de réalisation connu consiste en un convoyeur sans fin tournant autour d'axes placés à ses extrémités, et qui porte des claies sur lesquelles on pose les feuilles imprimées. Ce type de séchoir est aussi long que les tunnels à air chaud pulsé, du fait que seul un courant d'air très faible ou nul permet aux feuilles seulement posées de rester en place. Un autre inconvénient de ce type de séchoir est que les feuilles insuffisamment rigides touchent la claie précédente, ce qui limite la possibilité d'utilisation.A second known type of embodiment consists of an endless conveyor rotating around axes placed at its ends, and which carries racks on which the printed sheets are placed. This type of dryer is as long as the forced air tunnels, because only a very weak or no air flow allows only the laid leaves to stay in place. Another disadvantage of this type of dryer is that the insufficiently rigid sheets touch the previous rack, which limits the possibility of use.
Par ailleurs, le brevet US - A - 1 543 585 décrit un séchoir pour feuilles imprimées, comportant un convoyeur sans fin porté par un châssis et auquel sont fixés des cadres en U recevant les claies et un dispositif de chauffage pour les sécher pendant leur déplacement sur le convoyeur. Ce séchoir est complètement dépourvu de pinces d'amarrage des feuilles, qui peuvent de ce fait glisser hors des claies pendant leur déplacement.Furthermore, US Pat. No. 1,543,585 describes a dryer for printed sheets, comprising an endless conveyor carried by a frame and to which are fixed U-shaped frames receiving the racks and a heating device for drying them during their movement. on the conveyor. This dryer is completely devoid of sheet clamps, which can therefore slide out of the racks during their movement.
Le brevet GB - A - 793 216 décrit un séchoir dépourvu de claies, dans lequel les feuilles sont séchées par soufflage d'air chaud à plat sur une table située dans la partie supérieure du séchoir. L'absence de claies est très gênante puisque les feuilles peuvent venir se plaquer les unes sur les autres pendant leur déplacement. Par ailleurs, l'insertion des feuilles dans les pinces et leur déchargement se font en deux opérations consécutives distinctes.GB-A-793 216 describes a dryer without racks, in which the sheets are dried by blowing hot air flat on a table located in the upper part of the dryer. The absence of racks is very annoying since the leaves can come to press against each other during their movement. Furthermore, the insertion of the sheets into the tongs and their unloading are done in two separate consecutive operations.
Enfin, le brevet DE - A - 1 222 083 divulgue des pinces qui s'ouvrent lorsqu'elles passent entre deux rouleaux, une feuille pouvant alors être introduite dans la pince. Ce document ne prévoit pas d'utiliser ces pinces dans un séchoir pur feuilles imprimées par sérigraphie.Finally, patent DE-A-1 222 083 discloses tongs which open when they pass between two rollers, a sheet which can then be introduced into the tongs. This document does not envisage using these tongs in a pure sheet dryer printed by screen printing.
L'invention a pour but de remédier aux inconvénients des réalisations ci-dessus en proposant un séchoir pour feuilles imprimées par sérigraphie, comportant un convoyeur sans fin se déplaçant autour d'axes horizontaux portés par un châssis et auxquels sont fixées des claies adaptées pour recevoir les feuilles, ainsi qu'un dipositif de soufflage d'air sur celles-ci pour les sécher pendant leur déplacement sur le convoyeur. A cet effet, conformément à l'invention le bord de chaque claie est coudé attenant au convoyeur, et porte une série de pinces d'amarrage aptes à serrer le bord correspondant d'une feuille sur cette claie et des moyens de commande sont prévus pour assurer automatiquement en une seule action l'ouverture des pinces de chaque claie successivement avant le retrait d'une feuille séchée, les pinces se refermant sous l'action d'un organe élastique de rappel après l'introduction d'une feuille humide sur chaque claie.The invention aims to remedy the drawbacks of the above embodiments by providing a dryer for sheets printed by screen printing, comprising an endless conveyor moving around horizontal axes carried by a frame and to which are fixed racks adapted to receive the sheets, as well as a device for blowing air thereon to dry them during their movement on the conveyor. To this end, in accordance with the invention the edge of each rack is bent adjacent to the conveyor, and carries a series of mooring pliers capable of clamping the corresponding edge of a sheet on this rack and control means are provided for automatically ensure in a single action the opening of the clamps of each rack successively before the removal of a dried sheet, the clamps closing under the action of an elastic return member after the introduction of a wet sheet on each claie.
Dans ces conditions, les feuilles sont solidement amarrées à leurs claies de support, et ne tendent pas à glisser lorsque les claies pivotent à l'une ou l'autre extrémité du séchoir.Under these conditions, the sheets are securely moored to their support racks, and do not tend to slide when the racks pivot at one or the other end of the dryer.
Suivant un mode de réalisation de l'invention, les pinces d'amarrage sont constituées chacune par une lame coudée soumise à l'action de l'organe élastique de rappel et dont la branches située en face de la claie porte un ressort apte à s'appliquer sur le bord de la feuille à sécher placée sur la claie correspondante, cette même branche de chaque lame coudée venant alors en butée contre le bord coudé de la claie considérée.According to one embodiment of the invention, the mooring clamps each consist of a bent blade subjected to the action of the elastic return member and whose branches located in front of the rack carries a spring capable of s 'apply to the edge of the sheet to be dried placed on the corresponding rack, this same branch of each bent blade then coming into abutment against the bent edge of the rack considered.
Pendant son cycle de séchage, chaque feuille est donc solidement maintenue appliquée sur la claie associée par cette rangée de lames coudées, qui sont automatiquement relevées à la fin du cycle par les moyens de commande d'ouverture automatique précité, lequel est agencé pour provoquer cette ouverture seulement lorsque les feuilles sont à l'horizontale. Celles-ci peuvent ainsi être agrippées par des moyens mécaniques connus en soi pour être retirées du séchoir, sans avoir auparavant glissé sur la claie.During its drying cycle, each sheet is therefore firmly held applied to the associated rack by this row of bent blades, which are automatically raised at the end of the cycle by the abovementioned automatic opening control means, which is arranged to cause this opening only when the sheets are horizontal. These can thus be gripped by mechanical means known per se to be removed from the dryer, without having previously slipped on the rack.
D'autres particularités et avantages de l'invention apparaîtront au cours de la description qui va suivre. Aux dessins annexés donnés à titre d'exemple non limitatif, on a représenté une forme de réalisation du séchoir selon l'invention.
- La figure 1 est une vue en perspective d'un séchoir du type visé par l'invention;
- La figure 2 est une vue en perspective partielle à échelle agrandie d'une extrémité du séchoir de la figure 1, montrant une série de pinces d'amarrage équipant une claie;
- La figure 3 est une vue en élévation à grand échelle, montrant la cinématique de l'ouverture automatique d'une pince d'amarrage réalisée conformément à l'invention pour équiper le séchoir des figures 1 et 2.
- La figure 4 est une vue d'une pince en perspective.
- Figure 1 is a perspective view of a dryer of the type covered by the invention;
- Figure 2 is a partial perspective view on an enlarged scale of one end of the dryer of Figure 1, showing a series of mooring pliers fitted to a rack;
- FIG. 3 is a view in elevation on a large scale, showing the kinematics of the automatic opening of a mooring clamp produced in accordance with the invention for equipping the dryer of FIGS. 1 and 2.
- Figure 4 is a perspective view of pliers.
En se reportant aux figures 1 et 2, on voit un séchoir pour feuilles imprimées par sérigraphie, comportant un convoyeur sans fin 1, constitué de façon connue en soi par deux chaînes telles que 2 tournant dans des plans verticaux parallèles, autour d'axes terminaux 3 superposés, auxquels sont solidarisées des roues dentées 4.Referring to Figures 1 and 2, we see a dryer for sheets printed by screen printing, comprising an endless conveyor 1, constituted in a manner known per se by two chains such as 2 rotating in parallel vertical planes, around terminal axes 3 superimposed, to which are toothed wheels 4.
Ce convoyeur 1 est porté par un châssis 5 au milieu duquel est disposé un dispositif 6 de soufflage d'air d'un type connu en soi.This conveyor 1 is carried by a frame 5 in the middle of which is arranged a
Au convoyeur 1 sont fixées un ensemble de claies 7 constituées par des cadres rectangulaires destinés à recevoir chacun une feuille imprimée à sécher. Chaque claie 7 est fixée par son armature aux deux chaînes du convoyeur. Un système approprié leur permet d'être inclinées d'environ 25 degrés par rapport à la verticale dans la partie supérieure du séchoir, tout en restant verticales dans la partie inférieure. Les claies avec leurs feuilles imprimées à sécher s'introduisent dans le séchoir par l'extrémité de gauche sur la figure 1, tournent autour de l'extrémité de droite en passant dans un capot visible à la figure 1, puis reviennent sous le convoyeur 1 jusqu'à l'entrée du séchoir pour être retirées après avoir été séchées par l'air pulsé provenant du dispositif 6. Le trajet suivi par les claies 7 est symbolisé par les flèches portées sur la figure 2.To the conveyor 1 are fixed a set of
Conformément à l'invention, chaque claie 7, attenant au convoyeur, comporte un bord profilé 8 qui est coudé et porte une série de pinces d'amarrage 9 aptes à serrer le bord correspondant d'une feuille 11 (figure 3). Sur cette claie 7, il est également prévu, à l'une des extrémités du convoyeur, des moyens de commande aptes à assurer automatiquement, au début et à la fin de chaque cycle de séchage d'une feuille 11, l'ouverture et la fermeture des pinces 9 de chaque claie 7 afin de permettre lors d'un seul actionnement des pinces 9, l'introduction et le retrait d'une feuille 11 sur chaque claie.According to the invention, each
Le bord coudé 8 de chaque claie 7 comporte une partie 8b relevée au-dessus du plan de la claie, terminée par une petite branche 8a sensiblement parallèle à la surface de la claie 7.The
La fonction de la petite branche 8a est de servir de butée pour la lame 12, en limitant la grandeur de la force élastique de serrage appliquée sur la feuille 11 par la lame 12 et son ressort associé 16, tel que décrit ci-dessous.The function of the small branch 8a is to serve as a stop for the
Chaque série de pinces 9 est constitué, dans l'exemple représenté, par une rangée de lames coudées 12 (figure 3), montées rotativement autour d'axes ou goupilles 13 parallèles au côté attenant de la claie 7, solidaire du convoyeur sans fin 1. Les lames 12, métalliques de préférence, sont coudées dans l'exemple représenté en formant un angle d'environ 120 degrés, les axes 13 étant placés à l'intérieur de cet angle, et supportant les lames 12 par l'intermédiaire d'oreilles 14 solidaires des lames et dans lesquelles sont enfilés les axes 13.Each series of
Les lames coudées 12 sont sollicitées élastiquement vers la feuille 11 par des organes de rappel, pour maintenir la feuille 11 appliquée contre la claie 7. Dans t'exempte décrit, l'orange élastique de rappel de chaque pince 9 est un fil-ressort 15 enroulé autour de l'axe 13 entre les deux oreilles 14, et dont une extrémité 15a prend appui sous le bord 8 de la claie 7, tandis que son autre extrémité 15b est en appui contre une partie correspondante de la lame coudée 12. Le fil-ressort 15 exerce ainsi sur la branche de la lame 12 avec laquelle il est en contact par son extrémité 15b, une sollicitation élastique tendant à faire pivoter cette lame 12 autour de l'axe 13 vers la claie 7, comme indiqué par les flèches f sur la figure 3. Ce couple élastique est transmis à la feuille 11 par un ressort hélicoïdal 16 fixé à l'extrémité de la branche de la lame coudée 12 située en regard de la claie 7, ce ressort 16 étant appliqué contre la feuille 11 sous l'action du fil-ressort 15.The
Les moyens de commande d'ouverture automatiques de chaque série de pinces 9 porté par des axes 13, comprennent, dans l'exemple de réalisation représenté à la figure 3, une série de têtes telles que 17, agencées pour coopérer avec les lames coudées 12 et solidarisées avec un support transversal 18 porté par le châssis du séchoir.The automatic opening control means of each series of
Le support 18 est constitué par un organe tubulaire disposé transversalement et dont l'axe 24 est parallèle aux axes 13, au voisinage de l'extrémité d'entrée du convoyeur 1. La série de têtes 17 est solidarisée avec le support 18 par des tiges 19 soudées aux têtes 17 et au support 18. Ce dernier est en outre pourvu d'un bras transversal 21 pouvant coopérer avec un organe de manoeuvre du support 18 en rotation autour de son axe, cet organe étant ici un vérin 22. La tige 23 de celui-ci peut ainsi, lorsqu'elle est actionnée, faire pivoter le bras 21, et par conséquent le support 18 et l'ensemble des têtes 17 dans des plans verticaux parallèles, autour de l'axe transversal 24 du support 18, pour amener les têtes 17 de la position représentée à la figure 3, jusqu'à une position mettant en contact les têtes 17 avec les lames 12 de la claie 7 représentée horizontalement, jusqu'à obtenir l'ouverture des pinces de cette claie 7 - soit une rotation du support 18 dans le cas représenté à la figure 3, de 21 degrés environ dans le sens inverse des aiguilles d'une montre.The
Cette rotation, donce l'ouverture des pinces 9, s'opère à la fin du cycle de séchage lorsqu'une claie, chargée d'une feuille 11 sèche, vient de prendre la position horizontale, permettant ainsi le retrait de la feuille 11.This rotation, so the opening of the
Comme on le voit à la figure 3, la séquence d'ouverture et de fermeture automatiques d'une pince 9 se passe de la manière suivante. La claie pivotant du bas vers le haut dans le sens indiqué par la flèche R (voir aussi fig. 1 s'arrête à l'horizontale tandis que sa lame 12 se trouve à proximité de la tête associée 17 du dispositif d'ouverture automatique. La tige 23 du vérin 22 s'élève, et fait pivoter le support 18 qui entraîne la tête 17 et provoque l'ouverture des pinces 9, par pression des têtes 17 sur les lames 12 associées, cette pression venant contrarier l'action des fils-ressorts 15. La lame 12 et son ressort 16 basculent autour de l'axe 13 et s'écartent progressivement de la feuille 11 et de la claie 7. Pendant ce temps, les moyens précités non représentés retirent de façon connue en soi la feuille 11 séchée de sa claie de support. La claie horizontale ainsi débarrassée de sa feuille 11 va monter d'un cran avant de recevoir la nouvelle feuille humide. On voit sur la fig. 3 la position référencée A, dans laquelle la pince 9 est complètement ouverte, le ressort 16 étant écarté de la feuille 11, laquelle est inclinée d'environ 25 degrés sur l'horizontale avec sa claie 7 de support, au moment de l'introduction d'une nouvelle feuille humide dans le séchoir.As can be seen in FIG. 3, the sequence of automatic opening and closing of a
La rotation de la claie 7 et de sa série de pinces 9 se poursuivant autour de l'axe 24, les lames 12 sont maintenues ouvertes par les têtes 17 jusqu'à ce qu'elles échappent au contact de ces têtes, par une nouvelle manoeuvre du vérin 22, ce qui a pour effet de refermer les pinces 9 sur la nouvelle feuille humide venant d'être introduite (position référencée B sur la figure 3).The rotation of the
Le système d'amarrage par les pinces réalisé selon l'invention permet avantageusement de maintenir solidement les feuilles à sécher pendant toute la durée de leur cycle de séchage, et en particulier à la fin de celui-ci, lorsque les feuilles pivotent jusqu'à l'horizontale pour être retirées de l'appareil. Celles-ci ne risquent donc pas de se détacher ou de glisser vers l'extérieur de la claie avant d'être agrippées par le dispositif de préhension et de retrait. L'avantage essentiel du séchoir selon l'invention réside dans le fait que la solide fixation de chaque feuille permet de souffler sur celles-ci un important débit d'air ambiant, au lieu d'air chaud comme dans les tunnels à tapis. On supprime ainsi toute énergie de chauffage, ce qui réduit notablement le coût d'exploitation. De plus, l'absence de chaleur évite la déformation des feuilles, ce qui autorise des tirages où les couleurs peuvent se repérer entre elles d'une manière beaucoup plus précise que lorsqu'on utilise un tunnel à air chaud. En outre, du fait que grâce à la fiabilité du dispositif d'amarrage constitué par les pinces selon l'invention, on peut ventiler avec une force accrue, les feuilles sèchent plus rapidement. Corrélativement un nombre inférieur de claies est nécessaire pour sécher une quantité déterminée de feuilles dans un intervalle de temps donné, ce qui permet de diminuer l'encombrement de la machine en diminuant le nombre de claies qu'elle peut contenir.The clamping system produced according to the invention advantageously makes it possible to securely hold the sheets to be dried throughout the duration of their drying cycle, and in particular at the end of the latter, when the sheets pivot up to horizontal to be removed from the device. They therefore do not risk coming off or sliding towards the outside of the rack before being gripped by the gripping and removing device. The essential advantage of the dryer according to the invention lies in the fact that the solid fixing of each sheet makes it possible to blow a large flow of ambient air thereon, instead of hot air as in carpet tunnels. This eliminates all heating energy, which significantly reduces the operating cost. In addition, the absence of heat prevents the sheets from being deformed, which allows prints where the colors can identify each other in a much more precise way than when using a hot air tunnel. Furthermore, because of the reliability of the mooring device constituted by the clamps according to the invention, it is possible to ventilate with increased force, the sheets dry more quickly. Correspondingly, a lower number of racks is necessary to dry a determined quantity of sheets in a given time interval, which makes it possible to reduce the size of the machine by reducing the number of racks which it can contain.
L'invention n'est pas limitée à la forme de réalisation décrite et peut comporter des variantes d'exécution. Notamment, le dispositif d'ouverture et de fermeture automatiques peut être réalisé de toute autre façon équivalente à celle décrite et représentée à la figure 3, par exemple en disposant des cames fixes à peu près analogues aux têtes 17 et sur lesquelles les pinces viendraient s'ouvrir au moment d'atteindre l'horizontale.The invention is not limited to the embodiment described and may include variant embodiments. In particular, the automatic opening and closing device can be produced in any other way equivalent to that described and shown in FIG. 3, for example by having fixed cams roughly similar to the
Claims (5)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR7800305A FR2413974A1 (en) | 1978-01-06 | 1978-01-06 | DRYER FOR SCREEN-PRINTED SHEETS |
FR7800305 | 1978-01-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0003089A1 EP0003089A1 (en) | 1979-07-25 |
EP0003089B1 true EP0003089B1 (en) | 1981-08-12 |
Family
ID=9203176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19780400265 Expired EP0003089B1 (en) | 1978-01-06 | 1978-12-27 | Drier for silkscreen printed sheets |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0003089B1 (en) |
DE (1) | DE2860970D1 (en) |
FR (1) | FR2413974A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7674605B2 (en) | 2006-06-07 | 2010-03-09 | Bioalliance C.V. | Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same |
US8030023B2 (en) | 2005-02-02 | 2011-10-04 | Genentech, Inc. | Nucleic acid encoding DR5 antibodies and uses thereof |
US8691918B2 (en) | 2010-05-17 | 2014-04-08 | Emd Millipore Corporation | Stimulus responsive polymers for the purification of biomolecules |
US8697386B2 (en) | 2009-10-22 | 2014-04-15 | Genentech, Inc. | Methods and compositions for modulating hepsin activation of macrophage-stimulating protein |
US8771966B2 (en) | 2010-06-03 | 2014-07-08 | Genentech, Inc. | Immuno-PET imaging of antibodies and immunoconjugates and uses therefor |
US8999702B2 (en) | 2008-06-11 | 2015-04-07 | Emd Millipore Corporation | Stirred tank bioreactor |
US9266948B2 (en) | 2009-12-23 | 2016-02-23 | Genentech, Inc. | Anti-Bv8 antibodies and uses thereof |
US9708410B2 (en) | 2003-05-30 | 2017-07-18 | Janssen Biotech, Inc. | Anti-tissue factor antibodies and compositions |
US9873742B2 (en) | 2012-10-05 | 2018-01-23 | Genentech, Inc. | Methods for diagnosing and treating inflammatory bowel disease |
Families Citing this family (410)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5708142A (en) | 1994-05-27 | 1998-01-13 | Genentech, Inc. | Tumor necrosis factor receptor-associated factors |
US6998116B1 (en) | 1996-01-09 | 2006-02-14 | Genentech, Inc. | Apo-2 ligand |
US20050089958A1 (en) * | 1996-01-09 | 2005-04-28 | Genentech, Inc. | Apo-2 ligand |
US6030945A (en) * | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
CA2249206A1 (en) | 1996-04-01 | 1997-10-09 | Genentech, Inc. | Apo-2li and apo-3 apoptosis polypeptides |
US5851984A (en) * | 1996-08-16 | 1998-12-22 | Genentech, Inc. | Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides |
US6159462A (en) * | 1996-08-16 | 2000-12-12 | Genentech, Inc. | Uses of Wnt polypeptides |
US6462176B1 (en) | 1996-09-23 | 2002-10-08 | Genentech, Inc. | Apo-3 polypeptide |
US6136958A (en) * | 1996-09-30 | 2000-10-24 | Genentech, Inc. | Antibodies to vertebrate smoothened proteins |
US5990281A (en) | 1996-09-30 | 1999-11-23 | Genentech, Inc. | Vertebrate smoothened proteins |
JP3394540B2 (en) | 1997-01-31 | 2003-04-07 | ジェネンテク・インコーポレイテッド | O-fucosyltransferase |
AU735883C (en) * | 1997-06-13 | 2002-02-07 | Genentech Inc. | Protein recovery by chromatography followed by filtration upon a charged layer |
ATE393222T1 (en) | 1997-09-18 | 2008-05-15 | Genentech Inc | DCR3 POLYPEPTIDE, A TNFR HOMOLOGUE |
JP2001522584A (en) | 1997-10-10 | 2001-11-20 | ジェネンテク・インコーポレイテッド | Apo-3 ligand polypeptide |
EP2033970A3 (en) | 1997-10-29 | 2009-06-17 | Genentech, Inc. | Polypeptides and nucleic acids encoding the same |
US7192589B2 (en) | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
ES2305608T3 (en) | 1997-11-21 | 2008-11-01 | Genentech, Inc. | ANTIGENS TYPE A-33 AND ITS PHARMACOLOGICAL USES. |
NZ527900A (en) | 1997-12-03 | 2005-02-25 | Genentech Inc | PRO361 polypeptides and nucleic acids with homology to mucin and chitinase |
EP1947119A3 (en) | 1997-12-12 | 2012-12-19 | Genentech, Inc. | Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent |
WO1999036535A1 (en) | 1998-01-15 | 1999-07-22 | Genentech, Inc. | Apo-2 ligand |
EP2333069A3 (en) | 1998-05-15 | 2011-09-14 | Genentech, Inc. | Therapeutic uses of IL-17 homologous polypeptides |
EP1950300A3 (en) | 1998-11-18 | 2011-03-23 | Genentech, Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
EP2075335A3 (en) | 1998-12-22 | 2009-09-30 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
JP5456222B2 (en) | 1998-12-23 | 2014-03-26 | ジェネンテック, インコーポレイテッド | IL-1 related polypeptides |
HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
EP1956030B1 (en) | 1999-06-15 | 2009-11-11 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids endoding the same |
EP1189641B1 (en) | 1999-06-25 | 2009-07-29 | Genentech, Inc. | HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
ES2330301T3 (en) | 1999-08-27 | 2009-12-09 | Genentech, Inc. | DOSAGES FOR TREATMENT WITH ANTI-ERBB2 ANTIBODIES. |
EP2228446A1 (en) | 1999-12-01 | 2010-09-15 | Genentech, Inc. | Secreted and transmembrane polypeptieds and nucleic acids encoding the same |
EP2290081A3 (en) | 1999-12-23 | 2012-08-01 | Genentech, Inc. | IL-17 homologous polypeptide and therapeutic uses thereof |
EP1246917B1 (en) | 2000-01-13 | 2009-03-04 | Genentech, Inc. | Human stra6 polypeptides |
US6740520B2 (en) | 2000-03-21 | 2004-05-25 | Genentech, Inc. | Cytokine receptor and nucleic acids encoding the same |
EP2042597B1 (en) | 2000-06-23 | 2014-05-07 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
EP2077276A1 (en) | 2000-06-23 | 2009-07-08 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogensis |
ATE415978T1 (en) | 2000-07-27 | 2008-12-15 | Genentech Inc | SEQUENTIAL ADMINISTRATION OF CPT-11 AND APO-2L POLYPEPTIDE |
UA81743C2 (en) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS |
US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
ATE412009T1 (en) | 2000-08-24 | 2008-11-15 | Genentech Inc | METHOD FOR INHIBITING IL-22 INDUCED PAP1 |
EP1944317A3 (en) | 2000-09-01 | 2008-09-17 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU1344102A (en) | 2000-10-12 | 2002-04-22 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
US20020159996A1 (en) | 2001-01-31 | 2002-10-31 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
EP2340849A1 (en) | 2001-05-30 | 2011-07-06 | Genentech, Inc. | Anti-NGF antibodies for the treatment of various disorders |
US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
EP1992643A3 (en) | 2001-06-20 | 2008-12-10 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
CN1575338B (en) | 2001-08-29 | 2012-05-16 | 杰南技术公司 | Bv8 nucleic acids and polypeptides with mitogenic activity |
WO2003024392A2 (en) | 2001-09-18 | 2003-03-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
CN100374457C (en) | 2001-11-14 | 2008-03-12 | 森托科尔公司 | Anti-IL-6 antibodies, compositions, methods and uses |
WO2003057881A1 (en) | 2001-12-28 | 2003-07-17 | Chugai Seiyaku Kabushiki Kaisha | Method of stabilizing protein |
EP1575571A4 (en) | 2002-01-02 | 2008-06-25 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
US7452675B2 (en) | 2002-01-25 | 2008-11-18 | The Queen's Medical Center | Methods of screening for TRPM4b modulators |
CA2476518A1 (en) | 2002-02-22 | 2003-09-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP2110434A1 (en) | 2002-02-25 | 2009-10-21 | Genentech, Inc. | Type-1 cytokine receptor GLM-R |
EP2305710A3 (en) | 2002-06-03 | 2013-05-29 | Genentech, Inc. | Synthetic antibody phage libraries |
PT1585966E (en) | 2002-07-15 | 2012-02-20 | Hoffmann La Roche | Treatment of cancer with the anti-erbb2 antibody rhumab 2c4 |
WO2004024072A2 (en) | 2002-09-11 | 2004-03-25 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
ES2629602T5 (en) | 2002-09-11 | 2021-06-08 | Genentech Inc | Protein purification |
EP2444409A2 (en) | 2002-09-16 | 2012-04-25 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP1585482A4 (en) | 2002-09-25 | 2009-09-09 | Genentech Inc | Nouvelles compositions et methodes de traitement du psoriasis |
EP2322202A3 (en) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune diseases |
CA2503748A1 (en) | 2002-11-08 | 2004-05-27 | Genentech, Inc. | Compositions and methods for the treatment of natural killer cell related diseases |
WO2004047728A2 (en) | 2002-11-26 | 2004-06-10 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
PT1575517E (en) | 2002-12-24 | 2012-05-28 | Rinat Neuroscience Corp | Anti-ngf antibodies and methods using same |
JP4912144B2 (en) | 2003-03-12 | 2012-04-11 | ジェネンテック, インコーポレイテッド | Use of BV8 and / or EG-VEGF to promote hematopoiesis |
AU2003237792A1 (en) | 2003-04-01 | 2004-11-23 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
MXPA05012723A (en) | 2003-05-30 | 2006-02-08 | Genentech Inc | Treatment with anti-vegf antibodies. |
KR20060027801A (en) | 2003-06-05 | 2006-03-28 | 제넨테크, 인크. | Combination therapy for b cell disorders |
KR20060015646A (en) | 2003-06-13 | 2006-02-17 | 유니버시티 오브 피츠버그 | Monitoring immunologic, hematologic and inflammatory diseases |
SI1641822T1 (en) | 2003-07-08 | 2013-08-30 | Genentech, Inc. | Il-17 a/f heterologous polypeptides and therapeutic uses thereof |
ES2786568T3 (en) | 2003-07-28 | 2020-10-13 | Genentech Inc | Reduction of protein A leaching during protein A affinity chromatography |
EP2311468B1 (en) | 2003-08-08 | 2014-01-15 | Perseus Proteomics Inc. | Gene overexpressed in cancer |
WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP1689432B1 (en) | 2003-11-17 | 2009-12-30 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
US7750123B2 (en) | 2003-11-25 | 2010-07-06 | Dana Farber Cancer Institute, Inc. | Antibodies against SARS-CoV and methods of use thereof |
US7312320B2 (en) | 2003-12-10 | 2007-12-25 | Novimmune Sa | Neutralizing antibodies and methods of use thereof |
CA2548282A1 (en) | 2003-12-11 | 2005-06-30 | Genentech, Inc. | Methods and compositions for inhibiting c-met dimerization and activation |
US7968690B2 (en) | 2003-12-23 | 2011-06-28 | Rinat Neuroscience Corp. | Agonist anti-trkC antibodies and methods using same |
EP2168986A3 (en) | 2004-02-19 | 2010-07-28 | Genentech, Inc. | CDR-repaired antibodies |
US20060051345A1 (en) | 2004-06-04 | 2006-03-09 | Genentech, Inc. | Method for treating multiple sclerosis |
ZA200701183B (en) | 2004-07-20 | 2008-05-28 | Genentech Inc | Inhibitors of angiopoietin-like 4 protein, combinations, an their use |
EA016357B1 (en) | 2004-07-30 | 2012-04-30 | Ринат Ньюросайенс Корп. | Antibodies directed against amyloid-beta peptide and methods using same |
JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
US7964195B2 (en) | 2005-01-07 | 2011-06-21 | Diadexus, Inc. | Ovr110 antibody compositions and methods of use |
EP3698807A1 (en) | 2005-01-21 | 2020-08-26 | Genentech, Inc. | Fixed dosing of her antibodies |
US20060233791A1 (en) | 2005-02-15 | 2006-10-19 | Duke University | Anti-CD19 antibodies and uses in oncology |
AU2006216732C1 (en) | 2005-02-23 | 2017-07-20 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor |
US8278069B2 (en) | 2005-04-11 | 2012-10-02 | National Research Council Of Canada | Identification of a β-1,3-N-acetylgalactosaminyltransferase (CGTE) from Campylobacter jejuni LIO87 |
JO3058B1 (en) | 2005-04-29 | 2017-03-15 | Applied Molecular Evolution Inc | Anti-IL-6 Antibodies,Compositions,Methods and uses |
DE602006018458D1 (en) | 2005-04-29 | 2011-01-05 | Univ California | ANTIBODIES TO HISTONE MODIFICATIONS FOR CLINICAL CANCER DIAGNOSIS AND PROGNOSIS |
EP1885755A4 (en) | 2005-05-05 | 2009-07-29 | Univ Duke | Anti-cd19 antibody therapy for autoimmune disease |
PL1899364T3 (en) | 2005-05-17 | 2020-08-24 | University Of Connecticut | Compositions and methods for immunomodulation in an organism |
JP2009501006A (en) | 2005-06-30 | 2009-01-15 | セントカー・インコーポレーテツド | Anti-IL-23 antibodies, compositions, methods and uses |
SI2573114T1 (en) | 2005-08-10 | 2016-08-31 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
ES2664421T3 (en) | 2005-11-14 | 2018-04-19 | Teva Pharmaceuticals International Gmbh | Antagonist antibody directed against a peptide related to the calcitonin gene |
US8466263B2 (en) | 2005-12-02 | 2013-06-18 | Dana-Farber Cancer Institute, Inc. | Carbonic anhydrase IX (G250) anitbodies |
CN105859886A (en) | 2005-12-02 | 2016-08-17 | 健泰科生物技术公司 | Compositions and methods associated with antibodies that bind to IL-22 and IL-22R |
US7763245B2 (en) | 2005-12-15 | 2010-07-27 | Genentech, Inc. | Methods and compositions for targeting polyubiquitin |
HUE034269T2 (en) | 2005-12-29 | 2018-02-28 | Janssen Biotech Inc | Human anti-il-23 antibodies, compositions, methods and uses |
RU2450020C2 (en) | 2006-01-05 | 2012-05-10 | Дженентек, Инк. | ANTI-EphB4 ANTIBODIES AND METHODS OF USING SAID ANTIBODIES |
EP1982181B1 (en) | 2006-02-06 | 2010-12-15 | Rhode Island Hospital | Gpr30 estrogen receptor in breast cancers |
CA2638821A1 (en) | 2006-02-17 | 2007-10-11 | Genentech, Inc. | Gene disruptons, compositions and methods relating thereto |
EP2540741A1 (en) | 2006-03-06 | 2013-01-02 | Aeres Biomedical Limited | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
CA2646597A1 (en) | 2006-03-21 | 2007-09-27 | The Regents Of The University Of California | N-cadherin and ly6 e: targets for cancer diagnosis and therapy |
US20100278821A1 (en) | 2006-03-21 | 2010-11-04 | The Regents Of The University Of California | N-cadherin: target for cancer diagnosis and therapy |
ES2544957T3 (en) | 2006-03-21 | 2015-09-07 | Genentech, Inc. | Combined therapy involving alpha5beta1 antagonists |
EP2389948A1 (en) | 2006-03-23 | 2011-11-30 | Novartis AG | Anti-tumor cell antigen antibody therapeutics |
EP2614839A3 (en) | 2006-04-05 | 2015-01-28 | Genentech, Inc. | Method for using BOC/CDO to modulate hedgehog signaling |
WO2007131133A2 (en) | 2006-05-04 | 2007-11-15 | Genentech, Inc. | Methods and compositions relating to zpa polypeptides |
AR060978A1 (en) | 2006-05-30 | 2008-07-23 | Genentech Inc | ANTIBODIES AND IMMUNOCATE PLAYERS AND THEIR USES |
CA2654438A1 (en) | 2006-06-01 | 2008-03-27 | Genentech, Inc. | Crystal structure of crig and c3b:crig complex |
US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
EP2471815B1 (en) | 2006-07-11 | 2016-03-30 | University Of Medicine And Dentistry Of New Jersey | Proteins, nucleic acids encoding the same and associated methods of use |
ES2612383T3 (en) | 2006-07-19 | 2017-05-16 | The Trustees Of The University Of Pennsylvania | WSX-1 / IL-27 as a target for anti-inflammatory responses |
US8586006B2 (en) | 2006-08-09 | 2013-11-19 | Institute For Systems Biology | Organ-specific proteins and methods of their use |
BRPI0715703A2 (en) | 2006-08-22 | 2013-09-17 | G2 Inflammation Pty Ltd | anti-c5ar antibodies with enhanced properties |
JP2010501172A (en) | 2006-08-25 | 2010-01-21 | オンコセラピー・サイエンス株式会社 | Prognostic markers and therapeutic targets for lung cancer |
KR101161923B1 (en) | 2006-10-03 | 2012-07-03 | 유니버시티 오브 메디신 앤드 덴티스트리 오브 뉴 저지 | Atap peptides, nucleic acids encoding the same and associated methods of use |
SI2502938T1 (en) | 2006-10-27 | 2015-05-29 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
EP2097092A4 (en) | 2006-11-21 | 2010-04-07 | Modulation of rhamm (cd168) for selective adipose tissue development | |
JP5391073B2 (en) | 2006-11-27 | 2014-01-15 | ディアデクサス インコーポレーテッド | Ovr110 antibody compositions and methods of use |
US7875431B2 (en) | 2007-02-22 | 2011-01-25 | Genentech, Inc. | Methods for detecting inflammatory bowel disease |
WO2008109440A2 (en) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her dimerisation inhibitor based on low her3 expression |
RU2549701C2 (en) | 2007-05-07 | 2015-04-27 | Медиммун, Ллк | Anti-icos antibodies and their application in treatment of oncological, transplantation-associated and autoimmune diseases |
PL2173381T3 (en) | 2007-05-14 | 2014-03-31 | Novimmune Sa | Fc receptor-binding polypeptides with modified effector functions |
WO2008154249A2 (en) | 2007-06-08 | 2008-12-18 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
PT2164862E (en) | 2007-06-08 | 2015-10-29 | Australian Poultry Crc Pty Ltd | Clostridial toxin netb |
SI3597659T1 (en) | 2007-07-09 | 2023-04-28 | Genentech, Inc. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
TW200918089A (en) | 2007-07-16 | 2009-05-01 | Genentech Inc | Humanized anti-CD79b antibodies and immunoconjugates and methods of use |
JP5469600B2 (en) | 2007-07-16 | 2014-04-16 | ジェネンテック, インコーポレイテッド | Anti-CD79b antibody and immunoconjugate and method of use thereof |
MX2010001307A (en) | 2007-08-02 | 2010-07-30 | Novimmune Sa | Anti-rantes antibodies and methods of use thereof. |
US8691222B2 (en) | 2007-10-02 | 2014-04-08 | Genentech, Inc. | NLRR-1 antagonists and uses thereof |
US9464135B2 (en) | 2007-10-08 | 2016-10-11 | The Regents Of The University Of California | Epithelial membrane protein-2 (EMP2) and proliferative vitroretinopathy (PVR) |
SI2514436T1 (en) | 2007-11-07 | 2018-04-30 | Genentech, Inc. | Il-22 for use in treating microbial disorders |
KR20110015409A (en) | 2007-11-29 | 2011-02-15 | 제넨테크, 인크. | Gene expression markers for inflammatory bowel disease |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
AR069501A1 (en) | 2007-11-30 | 2010-01-27 | Genentech Inc | ANTI-VEGF ANTIBODIES (VASCULAR ENDOTELIAL GROWTH FACTOR) |
CA2707483A1 (en) | 2007-11-30 | 2009-06-11 | Wolfgang Fraunhofer | Protein formulations and methods of making same |
NZ586611A (en) | 2007-12-06 | 2012-09-28 | Dana Farber Cancer Inst Inc | Antibodies against influenza virus and methods of use thereof |
EP2231705A2 (en) | 2007-12-17 | 2010-09-29 | Pfizer Limited | Treatment of interstitial cystitis |
AU2008338313B2 (en) | 2007-12-18 | 2014-01-16 | Bioalliance C.V. | Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same |
CA3108119C (en) | 2008-01-15 | 2024-01-16 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
TWI472339B (en) | 2008-01-30 | 2015-02-11 | Genentech Inc | Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof |
SI2657253T1 (en) | 2008-01-31 | 2017-10-30 | Genentech, Inc. | Anti-CD79b antibodies and immunoconjugates and methods of use |
SG10201402815VA (en) | 2008-04-09 | 2014-09-26 | Genentech Inc | Novel compositions and methods for the treatment of immune related diseases |
JP6219556B2 (en) | 2008-05-16 | 2017-10-25 | ジェネンテック, インコーポレイテッド | Use of biomarkers for evaluation of treatment of gastrointestinal inflammatory disorders using beta7 integrin antagonists |
US9226934B2 (en) | 2008-06-02 | 2016-01-05 | The University Of Tokyo | Anti-cancer drug |
WO2009150623A1 (en) | 2008-06-13 | 2009-12-17 | Pfizer Inc | Treatment of chronic prostatitis |
US20120128684A1 (en) | 2008-08-25 | 2012-05-24 | Burnham Institute For Medical Research | Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use |
US8790642B2 (en) | 2008-08-29 | 2014-07-29 | Genentech, Inc. | Cross-reactive and bispecific anti-IL-17A/F antibodies |
KR20110051245A (en) | 2008-09-10 | 2011-05-17 | 제넨테크, 인크. | Methods for inhibiting ocular angiogenesis |
TWI516501B (en) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9 antagonists |
TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
EP2927244A1 (en) | 2008-09-19 | 2015-10-07 | MedImmune, LLC | Antibodies directed to DLL4 and uses thereof |
KR20190025057A (en) | 2008-10-14 | 2019-03-08 | 제넨테크, 인크. | Immunoglobulin variants and uses thereof |
US20110293605A1 (en) | 2008-11-12 | 2011-12-01 | Hasige Sathish | Antibody formulation |
JP2012512244A (en) | 2008-12-16 | 2012-05-31 | イー・エム・デイー・ミリポア・コーポレイシヨン | Protein purification |
KR20110101212A (en) | 2008-12-17 | 2011-09-15 | 제넨테크, 인크. | Hepatitis c virus combination therapy |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
MX2011006870A (en) | 2008-12-23 | 2011-07-19 | Genentech Inc | Immunoglobulin variants with altered binding to protein a. |
EP2379595A2 (en) | 2008-12-23 | 2011-10-26 | AstraZeneca AB | Targeted binding agents directed to 5 1 and uses thereof |
WO2010086828A2 (en) | 2009-02-02 | 2010-08-05 | Rinat Neuroscience Corporation | Agonist anti-trkb monoclonal antibodies |
SI3260136T1 (en) | 2009-03-17 | 2021-05-31 | Theraclone Sciences, Inc. | Human immunodeficiency virus (hiv) -neutralizing antibodies |
CA2754163C (en) | 2009-03-25 | 2019-04-09 | Genentech, Inc. | Anti-fgfr3 antibodies and methods using same |
AU2010236787A1 (en) | 2009-04-01 | 2011-11-10 | Genentech, Inc. | Anti-FcRH5 antibodies and immunoconjugates and methods of use |
PE20160652A1 (en) | 2009-05-05 | 2016-07-09 | Novimmune Sa | ANTIBODIES THAT JOIN IL-17F |
WO2010146511A1 (en) | 2009-06-17 | 2010-12-23 | Pfizer Limited | Treatment of overactive bladder |
MX2012000417A (en) | 2009-07-07 | 2012-02-08 | Genentech Inc | Diagnosis and treatment of autoimmune demyelinating diseases. |
EP2584049A3 (en) | 2009-07-20 | 2013-08-28 | Genentech, Inc. | Gene expression markers for Crohn's disease |
TW201106972A (en) | 2009-07-27 | 2011-03-01 | Genentech Inc | Combination treatments |
MX346115B (en) | 2009-08-06 | 2017-03-08 | Genentech Inc * | Method to improve virus removal in protein purification. |
US20110039300A1 (en) | 2009-08-10 | 2011-02-17 | Robert Bayer | Antibodies with enhanced adcc functions |
US20110038871A1 (en) | 2009-08-11 | 2011-02-17 | Veena Viswanth | Ccr2 inhibitors for treating conditions of the eye |
HUE048980T2 (en) | 2009-08-11 | 2020-08-28 | Hoffmann La Roche | Production of proteins in glutamine-free cell culture media |
US20110053223A1 (en) | 2009-08-14 | 2011-03-03 | Robert Bayer | Cell culture methods to make antibodies with enhanced adcc function |
US9428548B2 (en) | 2009-09-01 | 2016-08-30 | Genentech, Inc. | Enhanced protein purification through a modified protein A elution |
US9321823B2 (en) | 2009-09-02 | 2016-04-26 | Genentech, Inc. | Mutant smoothened and methods of using the same |
US9096877B2 (en) | 2009-10-07 | 2015-08-04 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
US20120207770A1 (en) | 2009-10-14 | 2012-08-16 | Nanyang Technological University | Antiproliferative agent |
NZ599337A (en) | 2009-10-22 | 2013-05-31 | Genentech Inc | Anti-hepsin antibodies and methods using same |
WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
RU2585488C2 (en) | 2009-11-05 | 2016-05-27 | Дженентек, Инк. | Methods and composition for secretion of heterologous polypeptides |
CN102612374A (en) | 2009-11-12 | 2012-07-25 | 霍夫曼-拉罗奇有限公司 | A method of promoting dendritic spine density |
NZ599405A (en) | 2009-11-24 | 2014-09-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
AR079217A1 (en) | 2009-11-30 | 2012-01-04 | Genentech Inc | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TUMOR TREATMENT |
TWI505836B (en) | 2009-12-11 | 2015-11-01 | Genentech Inc | Anti-vegf-c antibodies and methods using same |
KR101989628B1 (en) | 2009-12-21 | 2019-06-14 | 제넨테크, 인크. | Antibody formulation |
EP3450459B1 (en) | 2009-12-28 | 2021-05-26 | OncoTherapy Science, Inc. | Anti-cdh3 antibodies and uses thereof |
US20110159588A1 (en) | 2009-12-30 | 2011-06-30 | Kui Lin | Methods for Modulating a PDGF-AA Mediated Biological Response |
WO2011094759A2 (en) | 2010-02-01 | 2011-08-04 | The Regents Of The University Of California | Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies |
CN102933231B (en) | 2010-02-10 | 2015-07-29 | 伊缪诺金公司 | CD20 antibody and uses thereof |
AU2011217848B8 (en) | 2010-02-18 | 2015-09-24 | The Regents Of The University Of California | Integrin aVB8 neutralizing antibody |
MX2012009215A (en) | 2010-02-23 | 2012-11-23 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor. |
SA114360064B1 (en) | 2010-02-24 | 2016-01-05 | رينات نيوروساينس كوربوريشن | Antagonist anti-il-7 receptor antibodies and methods |
WO2011111007A2 (en) | 2010-03-11 | 2011-09-15 | Rinat Neuroscience Corporation | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING |
SI2552961T1 (en) | 2010-03-30 | 2018-02-28 | Janssen Biotech, Inc. | Humanized il-25 antibodies |
MA34291B1 (en) | 2010-05-03 | 2013-06-01 | Genentech Inc | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A TUMOR |
EP2566510A1 (en) | 2010-05-03 | 2013-03-13 | F. Hoffmann-La Roche AG | Compositions and methods useful for reducing the viscosity of protein-containing formulations |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
ES2637613T5 (en) | 2010-05-25 | 2022-07-20 | Hoffmann La Roche | Polypeptide purification procedures |
JP6050226B2 (en) | 2010-05-28 | 2016-12-21 | ジェネンテック, インコーポレイテッド | Lowering lactic acid levels and increasing polypeptide production by downregulating LDH and PDHK expression |
EP3957653A1 (en) | 2010-06-02 | 2022-02-23 | Dana Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
US20110311527A1 (en) | 2010-06-16 | 2011-12-22 | Allergan, Inc. | IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS |
NZ603581A (en) | 2010-06-19 | 2015-05-29 | Sloan Kettering Inst Cancer | Anti-gd2 antibodies |
WO2012019061A2 (en) | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
BR112013003279A2 (en) | 2010-08-13 | 2016-06-14 | Genentech In | "Methods for treating a disease, method for neutralizing or blocking il-1ß and / or il-18 activity, antibody, uses of an antibody and uses of a monoclonal antibody" |
SG10201506782XA (en) | 2010-08-27 | 2015-10-29 | Stem Centrx Inc | Notum protein modulators and methods of use |
PT3556396T (en) | 2010-08-31 | 2022-07-04 | Scripps Research Inst | Human immunodeficiency virus (hiv)-neutralizing antibodies |
CN106620693A (en) | 2010-09-03 | 2017-05-10 | 艾伯维施特姆森特克斯有限责任公司 | Novel modulators and methods of use |
WO2012030512A1 (en) | 2010-09-03 | 2012-03-08 | Percivia Llc. | Flow-through protein purification process |
WO2012047968A2 (en) | 2010-10-05 | 2012-04-12 | Genentech, Inc. | Mutant smoothened and methods of using the same |
AU2011325833C1 (en) | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
US20140199682A1 (en) | 2010-11-17 | 2014-07-17 | Sea Lane Biotechnologies, Llc | Influenza neutralizing agents |
WO2012071436A1 (en) | 2010-11-24 | 2012-05-31 | Genentech, Inc. | Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants |
EP2648748A1 (en) | 2010-12-08 | 2013-10-16 | Stem Centrx, Inc. | Novel modulators and methods of use |
WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
SA112330278B1 (en) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | Novel modulators and methods of use |
EP2685968A1 (en) | 2011-03-15 | 2014-01-22 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of influenza |
CA2831732C (en) | 2011-03-31 | 2019-12-31 | Genentech, Inc. | Use of a monoclonal anti-beta7 antibody for treating gastrointestinal inflammatory disorders |
CN103619881B (en) | 2011-04-07 | 2017-07-28 | 安姆根有限公司 | New EGFR associated proteins |
EP2714738B1 (en) | 2011-05-24 | 2018-10-10 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
EP2734546A1 (en) | 2011-07-18 | 2014-05-28 | Amgen Inc. | Apelin antigen-binding proteins and uses thereof |
JP6356607B2 (en) | 2011-11-02 | 2018-07-11 | ジェネンテック, インコーポレイテッド | Overload / elution chromatography |
WO2013063702A1 (en) | 2011-11-04 | 2013-05-10 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
EP2776470A2 (en) | 2011-11-11 | 2014-09-17 | Rinat Neuroscience Corporation | Antibodies specific for trop-2 and their uses |
WO2013093693A1 (en) | 2011-12-22 | 2013-06-27 | Rinat Neuroscience Corp. | Staphylococcus aureus specific antibodies and uses thereof |
US9249224B2 (en) | 2011-12-22 | 2016-02-02 | Rinat Neuroscience Corp. | Human growth hormone receptor antagonist antibodies and methods of use thereof |
US20130195851A1 (en) | 2011-12-23 | 2013-08-01 | Genentech, Inc. | Articles of manufacture and methods for co-administration of antibodies |
WO2013101771A2 (en) | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
WO2013106489A1 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Humanized antibodies with ultralong cdr3s |
WO2013106485A2 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
SI2812443T1 (en) | 2012-02-06 | 2019-10-30 | Inhibrx Inc | Cd47 antibodies and methods of use thereof |
DK2817338T3 (en) | 2012-02-24 | 2017-10-23 | Abbvie Stemcentrx Llc | DLL3 modulators and methods of use |
HUE037613T2 (en) | 2012-03-29 | 2018-09-28 | Novimmune Sa | Anti-tlr4 antibodies and uses thereof |
AU2013256010B2 (en) | 2012-05-04 | 2018-01-04 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use |
US20130336973A1 (en) | 2012-05-10 | 2013-12-19 | Zymeworks Inc. | Heteromultimer Constructs of Immunoglobulin Heavy Chains with Mutations in the Fc Domain |
AU2013274347B2 (en) | 2012-06-11 | 2018-03-08 | Amgen Inc. | Dual receptor antagonistic antigen-binding proteins and uses thereof |
DK2877494T3 (en) | 2012-07-23 | 2020-09-21 | La Jolla Inst Allergy & Immunology | PTPRS and proteoglycans in autoimmune disease |
AU2013322710A1 (en) | 2012-09-25 | 2015-04-16 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
EP2903641A2 (en) | 2012-10-04 | 2015-08-12 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
MX2015005874A (en) | 2012-11-09 | 2015-09-10 | Pfizer | Platelet-derived growth factor b specific antibodies and compositions and uses thereof. |
JP6392770B2 (en) | 2012-12-03 | 2018-09-19 | ノビミューン エスアー | Anti-CD47 antibody and method of use thereof |
KR102276974B1 (en) | 2013-02-06 | 2021-07-13 | 인히브릭스, 인크. | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
MX2015010682A (en) | 2013-02-22 | 2016-05-31 | Stemcentrx Inc | Novel antibody conjugates and uses thereof. |
CN110075293A (en) | 2013-03-13 | 2019-08-02 | 霍夫曼-拉罗奇有限公司 | Aoxidize reduced preparaton |
BR112015022210A8 (en) | 2013-03-13 | 2018-01-23 | Genentech Inc | antibody formulations |
HUE049707T2 (en) | 2013-03-13 | 2020-11-30 | Hoffmann La Roche | Formulations with reduced oxidation |
EA201890895A1 (en) | 2013-03-15 | 2019-02-28 | Зинджения, Инк. | MULTIVALENT AND MONOVALENT MULTIS-SPECIFIC COMPLEXES AND THEIR APPLICATION |
WO2014145098A1 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Cell culture compositions with antioxidants and methods for polypeptide production |
KR102207859B1 (en) | 2013-03-15 | 2021-01-27 | 메모리얼 슬로안 케터링 캔서 센터 | High affinity anti-gd2 antibodies |
AU2014227909C1 (en) | 2013-03-15 | 2021-11-25 | Dana-Farber Cancer Institute, Inc. | Flavivirus neutralizing antibodies and methods of use thereof |
US9447193B2 (en) | 2013-03-24 | 2016-09-20 | Development Center For Biotechnology | Methods for suppressing cancer by inhibition of TMCC3 |
RU2015145610A (en) | 2013-03-27 | 2017-05-04 | Дженентек, Инк. | APPLICATION OF BIOMARKERS FOR THE EVALUATION OF TREATMENT OF GASTROINTESTINAL INFLAMMATORY DISORDERS BY BETA7 INTEGRIN ANTAGONISTS |
US20160083698A1 (en) | 2013-04-19 | 2016-03-24 | The Regents Of The University Of California | Lone star virus |
MX2015015339A (en) | 2013-05-07 | 2016-07-15 | Rinat Neuroscience Corp | Anti-glucagon receptor antibodies and methods of use thereof. |
WO2015006686A1 (en) | 2013-07-12 | 2015-01-15 | Genentech, Inc. | Elucidation of ion exchange chromatography input optimization |
KR20160030936A (en) | 2013-07-16 | 2016-03-21 | 제넨테크, 인크. | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
CN105814074B (en) | 2013-07-18 | 2020-04-21 | 图鲁斯生物科学有限责任公司 | Humanized antibodies with ultralong complementarity determining regions |
EP3022224A2 (en) | 2013-07-18 | 2016-05-25 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
US10093978B2 (en) | 2013-08-12 | 2018-10-09 | Genentech, Inc. | Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms |
US10077304B2 (en) | 2013-08-14 | 2018-09-18 | The Governing Council Of The University Of Toronto | Antibodies against frizzled receptor |
EP3892294A1 (en) | 2013-08-28 | 2021-10-13 | AbbVie Stemcentrx LLC | Site-specific antibody conjugation methods and compositions |
EP3338793A1 (en) | 2013-08-28 | 2018-06-27 | AbbVie Stemcentrx LLC | Novel sez6 modulators and methods of use |
CA2922698C (en) | 2013-08-29 | 2023-01-03 | City Of Hope | Cell penetrating conjugates comprising non-cell penetrating antibodies covalently attached to one or more phosphorothioate nucleic acids |
SG11201602283UA (en) | 2013-09-27 | 2016-04-28 | Genentech Inc | Anti-pdl1 antibody formulations |
PE20160724A1 (en) | 2013-11-04 | 2016-08-04 | Glenmark Pharmaceuticals Sa | PRODUCTION OF T-CELL REDIRECTING HETERODIMERIC IMMUNOGLOBULINS |
SG10201810298VA (en) | 2013-11-13 | 2018-12-28 | Pfizer | Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof |
JP6667437B2 (en) | 2013-12-02 | 2020-03-18 | ベイラー カレッジ オブ メディスンBaylor College Of Medicine | Identification of novel polypeptide hormones for maintaining optimal weight and blood glucose |
WO2015087187A1 (en) | 2013-12-10 | 2015-06-18 | Rinat Neuroscience Corp. | Anti-sclerostin antibodies |
CA2934028A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
WO2015095410A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
EP3083692B1 (en) | 2013-12-17 | 2020-02-19 | F.Hoffmann-La Roche Ag | Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies |
PL3712174T3 (en) | 2013-12-24 | 2022-07-04 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
US9982041B2 (en) | 2014-01-16 | 2018-05-29 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
WO2016114819A1 (en) | 2015-01-16 | 2016-07-21 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
WO2015109212A1 (en) | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
WO2015120075A2 (en) | 2014-02-04 | 2015-08-13 | Genentech, Inc. | Mutant smoothened and methods of using the same |
AU2015231164B2 (en) | 2014-03-19 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Immunogenetic restriction on elicitation of antibodies |
DK3119431T3 (en) | 2014-03-21 | 2024-03-18 | Teva Pharmaceuticals Int Gmbh | ANTAGONISTS DIRECTED AGAINST CALCITONING-RELATED PEPTIDE AND METHODS OF USING THEREOF |
MX2016012282A (en) | 2014-03-27 | 2017-01-06 | Genentech Inc | Methods for diagnosing and treating inflammatory bowel disease. |
WO2015161267A2 (en) | 2014-04-18 | 2015-10-22 | The Board Of Trustees Of The Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to cd99 |
PT3148581T (en) | 2014-05-30 | 2020-01-06 | Henlix Biotech Co Ltd | Anti-epidermal growth factor receptor (egfr) antibodies |
LT3157561T (en) | 2014-06-17 | 2020-07-10 | Medimmune Limited | Improved alpha-v beta-8 antibodies |
TWI695011B (en) | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | Monoclonal antibodies against her2 epitope and methods of use thereof |
AU2015327781A1 (en) | 2014-10-03 | 2017-04-20 | Dana-Farber Cancer Institute, Inc. | Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof |
EP3699196A1 (en) | 2014-10-06 | 2020-08-26 | Dana Farber Cancer Institute, Inc. | Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof |
RU2020141422A (en) | 2014-11-05 | 2021-01-13 | Дженентек, Инк. | METHODS FOR OBTAINING TWO-STRAIN PROTEINS IN BACTERIA |
CA2966558C (en) | 2014-11-05 | 2024-03-12 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
WO2016081384A1 (en) | 2014-11-17 | 2016-05-26 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
TWI595006B (en) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | Anti-pd-1 antibodies and methods of use thereof |
EP3244907B1 (en) | 2015-01-13 | 2020-02-19 | City of Hope | Ctla4-binding protein peptide-linker masks |
MX2017009272A (en) | 2015-01-16 | 2018-04-11 | Cell penetrating antibodies. | |
WO2016118961A1 (en) | 2015-01-24 | 2016-07-28 | Academia Sinica | Cancer markers and methods of use thereof |
US10330683B2 (en) | 2015-02-04 | 2019-06-25 | Genentech, Inc. | Mutant smoothened and methods of using the same |
AU2016222683A1 (en) | 2015-02-26 | 2017-07-13 | Genentech, Inc. | Integrin beta7 antagonists and methods of treating crohn's disease |
JP6903587B2 (en) | 2015-04-03 | 2021-07-14 | ユーリカ セラピューティックス, インコーポレイテッド | Constructs targeting AFP peptide / MHC complexes and their use |
WO2016164835A1 (en) | 2015-04-08 | 2016-10-13 | Dana-Farber Cancer Institute, Inc. | Humanized influenza monoclonal antibodies and methods of use thereof |
CN114773476A (en) | 2015-04-13 | 2022-07-22 | 辉瑞公司 | Therapeutic antibodies and their use |
KR20170138556A (en) | 2015-05-01 | 2017-12-15 | 다나-파버 캔서 인스티튜트 인크. | Methods for mediating cytokine expression using anti-CCR4 antibodies |
AU2016265845B2 (en) | 2015-05-15 | 2020-10-08 | City Of Hope | Chimeric antigen receptor compositions |
WO2016187068A1 (en) | 2015-05-15 | 2016-11-24 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
WO2016196381A1 (en) | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Pd-l1 promoter methylation in cancer |
CN107810012A (en) | 2015-06-02 | 2018-03-16 | 豪夫迈·罗氏有限公司 | Use the composition and method of the anti-Antybody therapy sacred diseases of IL 34 |
MX2017016353A (en) | 2015-06-17 | 2018-05-02 | Genentech Inc | Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes. |
JP7026509B2 (en) | 2015-06-24 | 2022-02-28 | ヤンセン ファーマシューティカ エヌブイ | Anti-VISTA antibody and fragment |
CA3025896A1 (en) | 2015-07-23 | 2017-01-26 | The Regents Of The University Of California | Antibodies to coagulation factor xia and uses thereof |
JP7104462B2 (en) | 2015-08-06 | 2022-07-21 | シティ・オブ・ホープ | Cell-permeable protein-antibody conjugate and usage |
AU2016315892B2 (en) | 2015-09-02 | 2023-06-15 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for modulating T-cell mediated immune response |
IL293708A (en) | 2015-10-06 | 2022-08-01 | Genentech Inc | Method for treating multiple sclerosis |
KR20180064541A (en) | 2015-10-23 | 2018-06-14 | 화이자 인코포레이티드 | Anti-IL-2 antibodies and compositions and uses thereof |
CN108603037B (en) | 2015-12-10 | 2020-11-17 | 希望之城 | Cell penetrating cyanine conjugated antibodies |
KR20180103918A (en) | 2015-12-24 | 2018-09-19 | 코버스 파마슈티칼스, 인크. | How to cure cancer |
EP3397287A1 (en) | 2015-12-30 | 2018-11-07 | Genentech, Inc. | Formulations with reduced degradation of polysorbate |
CN108430455A (en) | 2015-12-30 | 2018-08-21 | 豪夫迈·罗氏有限公司 | Tryptophan derivative is used for the purposes of protein preparaton |
MX2018008347A (en) | 2016-01-08 | 2018-12-06 | Hoffmann La Roche | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies. |
US10221242B2 (en) | 2016-01-21 | 2019-03-05 | Pfizer Inc. | Antibodies specific for epidermal growth factor receptor variant III and their uses |
CN109073635A (en) | 2016-01-25 | 2018-12-21 | 豪夫迈·罗氏有限公司 | Method for measuring T cell dependence bispecific antibody |
CA3019952A1 (en) | 2016-02-04 | 2017-08-10 | Curis, Inc. | Mutant smoothened and methods of using the same |
CN116920085A (en) | 2016-02-12 | 2023-10-24 | 詹森药业有限公司 | anti-VISTA (B7H 5) antibodies |
AU2017241776A1 (en) | 2016-03-29 | 2018-10-11 | Janssen Biotech, Inc. | Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody |
WO2017173302A2 (en) | 2016-04-01 | 2017-10-05 | The Regents Of The University Of California | Inhibitors of integrin alpha 5 beta 1 and methods of use |
WO2017175058A1 (en) | 2016-04-07 | 2017-10-12 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
KR20190005966A (en) | 2016-05-10 | 2019-01-16 | 제넨테크, 인크. | Methods for reducing trisulfide bonds during recombinant production of polypeptides |
CN109563124A (en) | 2016-06-17 | 2019-04-02 | 豪夫迈·罗氏有限公司 | The purifying of multi-specificity antibody |
WO2018018039A2 (en) | 2016-07-22 | 2018-01-25 | Dana-Farber Cancer Institute, Inc. | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof |
CN106079858B (en) * | 2016-08-03 | 2017-05-17 | 钟晴晴 | Silk screen printer |
EP3494139B1 (en) | 2016-08-05 | 2022-01-12 | F. Hoffmann-La Roche AG | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
JP7250674B2 (en) | 2016-08-08 | 2023-04-03 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | CANCER TREATMENT AND DIAGNOSTIC METHOD |
WO2018035025A1 (en) | 2016-08-15 | 2018-02-22 | Genentech, Inc. | Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide |
WO2018045379A1 (en) | 2016-09-02 | 2018-03-08 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating b cell disorders |
US20190233505A1 (en) | 2016-09-06 | 2019-08-01 | Dana-Farber Cancer Institute, Inc. | Methods of treating or preventing zika virus infection |
TW201825674A (en) | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | Oncolytic virus expressing bispecific engager molecules |
EP3512885B1 (en) | 2016-09-16 | 2024-02-21 | Shanghai Henlius Biotech, Inc. | Anti-pd-1 antibodies |
EP3515937A1 (en) | 2016-09-23 | 2019-07-31 | Teva Pharmaceuticals International GmbH | Treating refractory migraine |
EA201990548A1 (en) | 2016-09-23 | 2019-09-30 | Тева Фармасьютикалз Интернэшнл Гмбх | TREATMENT OF CLUSTER HEAD PAIN |
CA3223687A1 (en) | 2016-09-29 | 2018-04-05 | The Regents Of The University Of California | Neutralizing antibodies to the .alpha.v.beta.8 integrin complex for immunotherapy |
MX2019003703A (en) | 2016-09-30 | 2020-08-13 | Janssen Biotech Inc | Safe and effective method of treating psoriasis with anti-il23 specific antibody. |
CA3040812A1 (en) | 2016-11-04 | 2018-05-11 | Novimmune Sa | Anti-cd19 antibodies and methods of use thereof |
US11008325B2 (en) | 2016-11-14 | 2021-05-18 | Virginia Commonwealth University | Inhibitors of cancer invasion, attachment, and/or metastasis |
AU2017362222A1 (en) | 2016-11-16 | 2019-05-30 | Janssen Biotech, Inc. | Method of treating psoriasis with anti-IL-23 specific antibody |
TW201825515A (en) | 2017-01-04 | 2018-07-16 | 美商伊繆諾金公司 | Met antibodies and immunoconjugates and uses thereof |
WO2018152496A1 (en) | 2017-02-17 | 2018-08-23 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Compositions and methods for the diagnosis and treatment of zika virus infection |
KR20190124753A (en) | 2017-03-03 | 2019-11-05 | 리나트 뉴로사이언스 코프. | Anti-GITR Antibodies and Methods of Use thereof |
EP3609915A1 (en) | 2017-04-12 | 2020-02-19 | Pfizer Inc | Antibodies having conditional affinity and methods of use thereof |
RU2665790C1 (en) | 2017-04-17 | 2018-09-04 | Закрытое Акционерное Общество "Биокад" | Monoclonal pd-l1 antibody |
EP3615569A1 (en) | 2017-04-25 | 2020-03-04 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Antibodies and methods for the diagnosis and treatment of epstein barr virus infection |
JOP20190256A1 (en) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | Newcastle disease viruses and uses thereof |
WO2018215835A1 (en) | 2017-05-26 | 2018-11-29 | Novimmune Sa | Anti-cd47 x anti-mesothelin antibodies and methods of use thereof |
EP3630841A1 (en) | 2017-06-02 | 2020-04-08 | Pfizer Inc. | Antibodies specific for flt3 and their uses |
CN111094334A (en) | 2017-07-19 | 2020-05-01 | 美国卫生与公众服务部 | Antibodies and methods for diagnosis and treatment of hepatitis B virus infection |
WO2019067015A1 (en) | 2017-09-29 | 2019-04-04 | City Of Hope | Chimeric antigen receptors and bispecific antibodies for treatment of mantle cell lymphoma |
RU2698048C2 (en) | 2017-10-03 | 2019-08-21 | Закрытое Акционерное Общество "Биокад" | Monoclonal antibody to il-5rα |
US11377500B2 (en) | 2018-02-01 | 2022-07-05 | Pfizer Inc. | Antibodies specific for CD70 and their uses |
JP2021515770A (en) | 2018-03-05 | 2021-06-24 | ヤンセン バイオテツク,インコーポレーテツド | Treatment of Crohn's disease using anti-IL-23 specific antibody |
WO2019175658A1 (en) | 2018-03-14 | 2019-09-19 | Novimmune Sa | Anti-cd3 epsilon antibodies and methods of use thereof |
CN108357203A (en) * | 2018-04-23 | 2018-08-03 | 广州市威顿彩印有限公司 | A kind of color printing producing line rotary blade type drying equipment and its application method |
WO2019213416A1 (en) | 2018-05-02 | 2019-11-07 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection |
US20190345245A1 (en) | 2018-05-11 | 2019-11-14 | Janssen Biotech, Inc. | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody |
EP3796983A2 (en) | 2018-05-23 | 2021-03-31 | Pfizer Inc. | Antibodies specific for gucy2c and uses thereof |
WO2019224385A2 (en) | 2018-05-24 | 2019-11-28 | Glenmark Pharmaceuticals S.A. | Combined bispecific antibody and immuno-oncology therapies |
EA202190092A1 (en) | 2018-06-21 | 2021-05-18 | Юманити Терапьютикс, Инк. | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS |
WO2019246557A1 (en) | 2018-06-23 | 2019-12-26 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor |
JP7376564B2 (en) | 2018-06-29 | 2023-11-08 | シティ・オブ・ホープ | CD6-targeted chimeric antigen receptor for treating certain autoimmune diseases |
WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
WO2020016838A2 (en) | 2018-07-18 | 2020-01-23 | Janssen Biotech, Inc. | Sustained response predictors after treatment with anti-il23 specific antibody |
CA3104147A1 (en) | 2018-07-18 | 2020-01-23 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent |
BR112021002130A2 (en) | 2018-08-08 | 2021-05-04 | Genentech, Inc. | liquid formulation, article of manufacture or kit and method for reducing oxidation of a polypeptide |
US20210221864A1 (en) | 2018-08-24 | 2021-07-22 | City Of Hope | Masked cytokine conjugates |
WO2020061381A1 (en) | 2018-09-19 | 2020-03-26 | La Jolla Institute For Immunology | Ptprs and proteoglycans in rheumatoid arthritis |
EP4249917A3 (en) | 2018-09-21 | 2023-11-08 | F. Hoffmann-La Roche AG | Diagnostic methods for triple-negative breast cancer |
AU2019375413A1 (en) | 2018-11-05 | 2021-05-27 | Genentech, Inc. | Methods of producing two chain proteins in prokaryotic host cells |
WO2020104943A2 (en) | 2018-11-20 | 2020-05-28 | Janssen Biotech, Inc. | Safe and effective method of treating psoriasis with anti-il-23 specific antibody |
TW202106876A (en) | 2019-04-19 | 2021-02-16 | 日商中外製藥股份有限公司 | Chimeric receptor recognizing modification site of antibody |
JP2022534020A (en) | 2019-05-23 | 2022-07-27 | ヤンセン バイオテツク,インコーポレーテツド | Methods of treating inflammatory bowel disease with combination therapy of antibodies against IL-23 and TNF-alpha |
MX2021014882A (en) | 2019-06-03 | 2022-03-25 | Janssen Biotech Inc | Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis. |
AR119264A1 (en) | 2019-06-05 | 2021-12-09 | Genentech Inc | METHOD FOR REUSE OF CHROMATOGRAPHY |
JPWO2021010326A1 (en) | 2019-07-12 | 2021-01-21 | ||
JP2022541652A (en) | 2019-07-26 | 2022-09-26 | ヴァンダービルト ユニバーシティ | Human monoclonal antibody against enterovirus D68 |
EP4013788A1 (en) | 2019-08-12 | 2022-06-22 | Purinomia Biotech, Inc. | Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells |
WO2021028752A1 (en) | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Anti-tfn antibodies for treating type i diabetes |
WO2021138454A1 (en) | 2019-12-30 | 2021-07-08 | City Of Hope | Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers |
IL295310A (en) | 2020-02-11 | 2022-10-01 | Univ Vanderbilt | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov- 2) |
WO2021195385A1 (en) | 2020-03-26 | 2021-09-30 | Vanderbilt University | HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2) |
PL4045533T3 (en) | 2020-03-26 | 2024-04-15 | Vanderbilt University | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) |
WO2021205325A1 (en) | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Anti-gucy2c antibodies and uses thereof |
US11634477B2 (en) | 2020-04-28 | 2023-04-25 | The Rockefeller University | Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof |
KR20230025691A (en) | 2020-06-16 | 2023-02-22 | 제넨테크, 인크. | Methods and compositions for treating triple negative breast cancer |
TW202216779A (en) | 2020-07-17 | 2022-05-01 | 美商輝瑞股份有限公司 | Therapeutic antibodies and their uses |
AR123997A1 (en) | 2020-11-04 | 2023-02-01 | Univ Rockefeller | NEUTRALIZING ANTIBODIES AGAINST SARS-CoV-2 |
US20220227844A1 (en) | 2021-01-15 | 2022-07-21 | The Rockefeller University | Neutralizing anti-sars-cov-2 antibodies |
JP2024503724A (en) | 2021-01-20 | 2024-01-26 | オンコレスポンス,インク. | Immunomodulatory antibodies and their uses |
EP4305062A1 (en) | 2021-03-12 | 2024-01-17 | Janssen Biotech, Inc. | Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody |
IL305802A (en) | 2021-03-12 | 2023-11-01 | Janssen Biotech Inc | Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody |
AU2022241935A1 (en) | 2021-03-22 | 2023-09-28 | Novimmune S.A. | Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof |
WO2022200389A1 (en) | 2021-03-22 | 2022-09-29 | Novimmune S.A. | Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof |
WO2022235867A2 (en) | 2021-05-06 | 2022-11-10 | The Rockefeller University | Neutralizing anti-sars- cov-2 antibodies and methods of use thereof |
WO2023073615A1 (en) | 2021-10-29 | 2023-05-04 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
WO2023081471A1 (en) | 2021-11-05 | 2023-05-11 | Dana-Farber Cancer Institute, Inc. | Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof |
WO2023084488A1 (en) | 2021-11-15 | 2023-05-19 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
US20230159633A1 (en) | 2021-11-23 | 2023-05-25 | Janssen Biotech, Inc. | Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody |
WO2023147399A1 (en) | 2022-01-27 | 2023-08-03 | The Rockefeller University | Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof |
CN114485122A (en) * | 2022-02-24 | 2022-05-13 | 广西青松木业有限公司 | Tunnel type timber veneer drying production line |
WO2023178357A1 (en) | 2022-03-18 | 2023-09-21 | Evolveimmune Therapeutics, Inc. | Bispecific antibody fusion molecules and methods of use thereof |
WO2023187707A1 (en) | 2022-03-30 | 2023-10-05 | Janssen Biotech, Inc. | Method of treating mild to moderate psoriasis with il-23 specific antibody |
GB202204813D0 (en) | 2022-04-01 | 2022-05-18 | Bradcode Ltd | Human monoclonal antibodies and methods of use thereof |
WO2023192622A1 (en) | 2022-04-01 | 2023-10-05 | Genentech, Inc. | Hydroxypropyl methyl cellulose derivatives to stabilize polypeptides |
WO2023215498A2 (en) | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
WO2023223265A1 (en) | 2022-05-18 | 2023-11-23 | Janssen Biotech, Inc. | Method for evaluating and treating psoriatic arthritis with il23 antibody |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1543585A (en) * | 1923-03-24 | 1925-06-23 | Heekin Can Company | Synchronized press and oven conveyer |
GB793216A (en) * | 1956-02-18 | 1958-04-09 | James Arthur Black | Improvements in or relating to a method of and machine or apparatus for drying coated sheet stock |
DE1222083B (en) * | 1962-04-02 | 1966-08-04 | Rank Xerox Ltd | Device for transporting paper or the like sheets |
-
1978
- 1978-01-06 FR FR7800305A patent/FR2413974A1/en active Granted
- 1978-12-27 EP EP19780400265 patent/EP0003089B1/en not_active Expired
- 1978-12-27 DE DE7878400265T patent/DE2860970D1/en not_active Expired
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9708410B2 (en) | 2003-05-30 | 2017-07-18 | Janssen Biotech, Inc. | Anti-tissue factor antibodies and compositions |
US8030023B2 (en) | 2005-02-02 | 2011-10-04 | Genentech, Inc. | Nucleic acid encoding DR5 antibodies and uses thereof |
US8029783B2 (en) | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
US8409570B2 (en) | 2005-02-02 | 2013-04-02 | Genentech, Inc. | Method of inducing apoptosis using anti-DR5 antibodies |
US7674605B2 (en) | 2006-06-07 | 2010-03-09 | Bioalliance C.V. | Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same |
US8999702B2 (en) | 2008-06-11 | 2015-04-07 | Emd Millipore Corporation | Stirred tank bioreactor |
US8697386B2 (en) | 2009-10-22 | 2014-04-15 | Genentech, Inc. | Methods and compositions for modulating hepsin activation of macrophage-stimulating protein |
US9266948B2 (en) | 2009-12-23 | 2016-02-23 | Genentech, Inc. | Anti-Bv8 antibodies and uses thereof |
US9217048B2 (en) | 2010-05-17 | 2015-12-22 | Emd Millipore Corporation | Stimulus responsive polymers for the purification of biomolecules |
US8691918B2 (en) | 2010-05-17 | 2014-04-08 | Emd Millipore Corporation | Stimulus responsive polymers for the purification of biomolecules |
US9731288B2 (en) | 2010-05-17 | 2017-08-15 | Emd Millipore Corporation | Stimulus responsive polymers for the purification of biomolecules |
US8771966B2 (en) | 2010-06-03 | 2014-07-08 | Genentech, Inc. | Immuno-PET imaging of antibodies and immunoconjugates and uses therefor |
US9873742B2 (en) | 2012-10-05 | 2018-01-23 | Genentech, Inc. | Methods for diagnosing and treating inflammatory bowel disease |
US11091551B2 (en) | 2012-10-05 | 2021-08-17 | Genentech, Inc. | Methods for diagnosing and treating inflammatory bowel disease |
Also Published As
Publication number | Publication date |
---|---|
EP0003089A1 (en) | 1979-07-25 |
FR2413974B1 (en) | 1982-12-03 |
DE2860970D1 (en) | 1981-11-12 |
FR2413974A1 (en) | 1979-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0003089B1 (en) | Drier for silkscreen printed sheets | |
BE1004555A3 (en) | MACHINE FOR THE BACON skinning. | |
EP0229554A1 (en) | Apparatus for applying fastening elements to conveyor belts or the like | |
EP0424290B1 (en) | Positioning device for a product in the form of a flexible sheet | |
EP0780065A1 (en) | Assembling device for the upper and the sole of a shoe | |
FR2541562A1 (en) | Automatic vine grafting method and machine for applying this method | |
EP0086867B1 (en) | Portable labelling machine | |
EP0220967B1 (en) | Conveyor for containers | |
EP0578551B1 (en) | Improvements in printing machines, especially for screen printers | |
CH642269A5 (en) | SKI BRAKE. | |
FR2575629A1 (en) | DEVICE FOR AUTOMATICALLY MOUNTING ON A SUBSTRATE OF CIRCUIT CIRCUIT ELEMENTS | |
EP0274296A1 (en) | Method for automatically lidding containers, such as cups, device for carrying out this method, and packaging machine equipped with this device | |
EP0320342B1 (en) | Bending machine | |
EP0252844B1 (en) | Automatic apparatus for treating, and in particular for cutting, web material | |
FR2552408A1 (en) | DEVICE FOR FIXING RIBBON SECTIONS ON PIECES OF FABRIC | |
FR2733491A1 (en) | DEVICE FOR RELEASING PRINTED COPIES OF A BLADE WHEEL DEVICE | |
EP0219444B1 (en) | Log-splitting machine with a rotatable conical splitting member | |
FR2649086A1 (en) | Distributor of flexible supports | |
FR2766411A1 (en) | Thermal transfer paper printer | |
FR2477504A1 (en) | Folding and gluing adhesive tab applicator - has work table and lever operated bending die at one end acting on edges of documents | |
EP0249568A1 (en) | Yarn package handler for hydro-extractors | |
CH402388A (en) | Apparatus for shaping articles from a thermoplastic sheet | |
EP0259235A1 (en) | Machine for automatically picking up skins or the like from a pile | |
BE1001017A6 (en) | Automatic device for securing free end of plastic material roll - comprises sensor detecting position of roll and its end which is raised by air jet and heat-sealed | |
CH632712A5 (en) | Labelling device, particularly for bottles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): BE CH DE GB IT LU NL SE |
|
17P | Request for examination filed | ||
ITF | It: translation for a ep patent filed |
Owner name: ST. ASSOC. MARIETTI & PIPPARELLI |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): BE CH DE GB IT LU NL SE |
|
REF | Corresponds to: |
Ref document number: 2860970 Country of ref document: DE Date of ref document: 19811112 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19811231 |
|
PLBI | Opposition filed |
Free format text: ORIGINAL CODE: 0009260 |
|
26 | Opposition filed |
Opponent name: SVECIA SILKSCREEN MASKINER AB Effective date: 19820218 |
|
PLAB | Opposition data, opponent's data or that of the opponent's representative modified |
Free format text: ORIGINAL CODE: 0009299OPPO |
|
R26 | Opposition filed (corrected) |
Opponent name: LINDBLOM, ERIK J. Effective date: 19820218 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 19831031 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19831130 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19831231 Year of fee payment: 6 |
|
PLBN | Opposition rejected |
Free format text: ORIGINAL CODE: 0009273 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: OPPOSITION REJECTED |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19841221 Year of fee payment: 7 Ref country code: CH Payment date: 19841221 Year of fee payment: 7 |
|
27O | Opposition rejected |
Effective date: 19840722 |
|
NLR2 | Nl: decision of opposition | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19851231 Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Effective date: 19861231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19870701 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee | ||
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19871228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Effective date: 19871231 |
|
BERE | Be: lapsed |
Owner name: SILIUM S.F.A.R.L. Effective date: 19871231 Owner name: DAVID BERNARD Effective date: 19871231 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19880901 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19881117 |
|
EUG | Se: european patent has lapsed |
Ref document number: 78400265.1 Effective date: 19880912 |